{"id":690369,"date":"2024-03-05T17:42:02","date_gmt":"2024-03-05T17:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=690369"},"modified":"2024-03-05T17:42:02","modified_gmt":"2024-03-05T17:42:02","slug":"hypertrophic-cardiomyopathy-treatment-market-to-exhibit-impressive-growth-by-2023-predicts-delveinsight-key-companies-cytokinetics-bristolmyers-squibb-imbria-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypertrophic-cardiomyopathy-treatment-market-to-exhibit-impressive-growth-by-2023-predicts-delveinsight-key-companies-cytokinetics-bristolmyers-squibb-imbria-pharmaceuticals_690369.html","title":{"rendered":"Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies &#8211; Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1709649566.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1709649566.jpeg\" alt=\"Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>Hypertrophic Cardiomyopathy Market Insights<\/strong>&nbsp;report includes a comprehensive understanding of current treatment practices, hypertrophic cardiomyopathy emerging drugs, market share of individual therapies, and current and forecasted hypertrophic cardiomyopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Hypertrophic Cardiomyopathy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight&rsquo;s analysis, the hypertrophic cardiomyopathy market is anticipated to grow at a significant CAGR by 2032.<\/li>\n<li>In the assessment done by DelveInsight, the estimated total diagnosed cases of HCM in the 7MM were&nbsp;<strong>239K<\/strong>&nbsp;in 2022. The highest diagnosed cases of HCM were accounted by the US in 2022 which were approximately&nbsp;<strong>48%<\/strong>&nbsp;of the 7MM. These cases are expected to increase during the forecast period (2023&ndash;2032).&nbsp;<\/li>\n<li>Leading hypertrophic cardiomyopathy companies such as&nbsp;<strong>Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis,&nbsp;<\/strong>and others are developing novel hypertrophic cardiomyopathy drugs that can be available in the hypertrophic cardiomyopathy market in the coming years.<\/li>\n<li>Some of the key therapies for hypertrophic cardiomyopathy treatment include&nbsp;<strong>Aficamten, Mavacamten, IMB-1018972, TN-201, LCZ696,&nbsp;<\/strong>and others.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Discover which therapies are expected to grab the major hypertrophic cardiomyopathy market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Hypertrophic Cardiomyopathy Market Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hypertrophic Cardiomyopathy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hypertrophic cardiomyopathy is a prevalent inherited cardiac condition that significantly contributes to cardiovascular morbidity and mortality across all age groups. HCM is characterized by unexplained left ventricular hypertrophy and a non-dilated left ventricle, often with preserved or increased ejection fraction. This hypertrophy typically exhibits asymmetry, with the most pronounced thickening in the basal interventricular septum. Over a dozen genes associated with sarcomere proteins have been linked to the development of hypertrophic cardiomyopathy (HCM).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypertrophic Cardiomyopathy Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Hypertrophic Cardiomyopathy Prevalent Cases<\/li>\n<li>Hypertrophic Cardiomyopathy Diagnosed Cases<\/li>\n<li>Hypertrophic Cardiomyopathy Gender-specific Diagnosed Cases<\/li>\n<li>Hypertrophic Cardiomyopathy Type-specific Diagnosed Cases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving hypertrophic cardiomyopathy epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Hypertrophic Cardiomyopathy Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hypertrophic Cardiomyopathy Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CAMZYOS (Mavacamten)&nbsp;<\/strong>is the first FDA-approved cardiac myosin inhibitor designed to address the needs of adults suffering from symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy. Its primary purpose is to enhance functional capacity and alleviate symptoms. CAMZYOS is a selective, allosteric, and reversible inhibitor that specifically targets cardiac myosin. By modulating the number of myosin heads capable of entering the &lsquo;on actin&rsquo; state, it reduces the likelihood of force production during systolic and diastolic cross-bridge formation.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the FDA-approved drugs for hypertrophic cardiomyopathy @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for&nbsp;Hypertrophic Cardiomyopathy Treatment&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Hypertrophic Cardiomyopathy Therapies and Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Aficamten: Cytokinetics<\/li>\n<li>Mavacamten: Bristol-Myers Squibb<\/li>\n<li>IMB-1018972: Imbria Pharmaceuticals, Inc.<\/li>\n<li>TN-201: Tenaya Therapeutics<\/li>\n<li>LCZ696: Novartis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about hypertrophic cardiomyopathy clinical trials, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Hypertrophic Cardiomyopathy&nbsp;Treatment Drugs&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hypertrophic Cardiomyopathy Market Dynamics<\/strong><\/p>\n<p style=\"text-align: justify;\">The hypertrophic cardiomyopathy market dynamics are anticipated to change in the coming years. In the realm of hypertrophic cardiomyopathy treatment, various approaches exist alongside pharmacotherapy, including&nbsp;<strong>septal myectomy and septal alcohol ablation<\/strong>, which are considered comparable procedures for addressing hypertrophic obstructive cardiomyopathy (HOCM). The pivotal tool for diagnosing HCM remains&nbsp;<strong>echocardiography<\/strong>, and the potential role of MRI in assessing the risk of sudden cardiac death is on the horizon. It is crucial to differentiate between&nbsp;<strong>genetically mediated phenocopies and physiologic remodeling<\/strong>&nbsp;resulting from fitness, as these distinctions can significantly impact management strategies. As our understanding of the genetic basis of HCM continues to expand,&nbsp;<strong>genetic testing<\/strong>&nbsp;holds promise for providing deeper insights.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Hypertrophic Cardiomyopathy&nbsp;Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Therapeutic Assessment:&nbsp;<\/strong>Hypertrophic Cardiomyopathy current marketed and emerging therapies<\/li>\n<li><strong>Hypertrophic Cardiomyopathy<\/strong>&nbsp;<strong>Market Dynamics:<\/strong>&nbsp;Attribute Analysis of Emerging Hypertrophic Cardiomyopathy Drugs<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp;SWOT analysis and Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Hypertrophic Cardiomyopathy Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about hypertrophic cardiomyopathy drugs in development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Hypertrophic Cardiomyopathy Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Hypertrophic Cardiomyopathy (HCM)<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Hypertrophic Cardiomyopathy (HCM)<\/p>\n<p style=\"text-align: justify;\">4. Hypertrophic Cardiomyopathy (HCM): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Hypertrophic Cardiomyopathy (HCM): Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Hypertrophic Cardiomyopathy (HCM) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Hypertrophic Cardiomyopathy (HCM)&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Hypertrophic Cardiomyopathy (HCM) Treatment<\/p>\n<p style=\"text-align: justify;\">11. Hypertrophic Cardiomyopathy (HCM)&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Hypertrophic Cardiomyopathy (HCM)&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Hypertrophic Cardiomyopathy (HCM): Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Hypertrophic Cardiomyopathy (HCM)<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hypertrophic-cardiomyopathy-treatment-market-to-exhibit-impressive-growth-by-2023-predicts-delveinsight-key-companies-cytokinetics-bristolmyers-squibb-imbria-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/primary-research-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hypertrophic-cardiomyopathy-treatment-market-to-exhibit-impressive-growth-by-2023-predicts-delveinsight-key-companies-cytokinetics-bristolmyers-squibb-imbria-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s&nbsp;Hypertrophic Cardiomyopathy Market Insights&nbsp;report includes a comprehensive understanding of current treatment practices, hypertrophic cardiomyopathy emerging drugs, market share of individual therapies, and current and forecasted hypertrophic cardiomyopathy market size from 2019 to 2032, segmented into 7MM [the United States, the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hypertrophic-cardiomyopathy-treatment-market-to-exhibit-impressive-growth-by-2023-predicts-delveinsight-key-companies-cytokinetics-bristolmyers-squibb-imbria-pharmaceuticals_690369.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-690369","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=690369"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690369\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=690369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=690369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=690369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}